Theratechnologies Inc. (NASDAQ:THTX - Get Free Report) traded up 0.5% during trading on Wednesday . The stock traded as high as $2.78 and last traded at $2.76. 383,922 shares traded hands during mid-day trading, a decline of 52% from the average session volume of 799,915 shares. The stock had previously closed at $2.74.
Wall Street Analyst Weigh In
Several analysts have issued reports on the stock. Jones Trading raised shares of Theratechnologies from a "hold" rating to a "strong-buy" rating in a research report on Friday, April 11th. Research Capitl raised shares of Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.
Read Our Latest Report on Theratechnologies
Theratechnologies Price Performance
The firm has a market capitalization of $120.47 million, a price-to-earnings ratio of -26.20 and a beta of 0.56. The firm's 50 day moving average is $2.02 and its 200 day moving average is $1.72.
Institutional Trading of Theratechnologies
Several hedge funds and other institutional investors have recently bought and sold shares of THTX. Hillsdale Investment Management Inc. acquired a new stake in Theratechnologies in the 4th quarter valued at about $108,000. Cyndeo Wealth Partners LLC acquired a new position in shares of Theratechnologies in the first quarter valued at approximately $42,000. Virtu Financial LLC bought a new stake in shares of Theratechnologies in the fourth quarter worth $40,000. BNP Paribas Financial Markets bought a new stake in shares of Theratechnologies in the fourth quarter worth $36,000. Finally, Wealthspire Advisors LLC raised its position in Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock worth $129,000 after acquiring an additional 20,000 shares in the last quarter.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Articles
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
